Smith PD - Search Results

1

Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.

Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C, Leasure J, Smith PD, Kurmasheva RT, Mo X, Fouladi M, Houghton PJ. Studebaker A, et al. Among authors: smith pd. Pediatr Blood Cancer. 2015 Oct;62(10):1768-74. doi: 10.1002/pbc.25579. Epub 2015 May 15. Pediatr Blood Cancer. 2015. PMID: 25981859 Free PMC article.

2

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. Friday BB, et al. Among authors: smith pd. Cancer Res. 2008 Aug 1;68(15):6145-53. doi: 10.1158/0008-5472.CAN-08-1430. Cancer Res. 2008. PMID: 18676837

3

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. Dry JR, et al. Among authors: smith pd. Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215513 Free PMC article.

4

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Gopal YN, et al. Among authors: smith pd. Cancer Res. 2010 Nov 1;70(21):8736-47. doi: 10.1158/0008-5472.CAN-10-0902. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959481 Free PMC article.

5

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL, Wilkinson RW, Guichard SM, Smith PD. Holt SV, et al. Among authors: smith pd. Cancer Res. 2012 Apr 1;72(7):1804-13. doi: 10.1158/0008-5472.CAN-11-1780. Epub 2012 Jan 23. Cancer Res. 2012. PMID: 22271687

6

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD. Holt SV, et al. Among authors: smith pd. Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16. Br J Cancer. 2012. PMID: 22343622 Free PMC article.

7

Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.

Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJ. Bid HK, et al. Among authors: smith pd. Clin Cancer Res. 2013 Dec 15;19(24):6716-29. doi: 10.1158/1078-0432.CCR-13-0842. Epub 2013 Oct 16. Clin Cancer Res. 2013. PMID: 24132923 Free PMC article.

8

Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.

Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M. Zhang W, et al. Mol Cancer Ther. 2014 Jul;13(7):1848-59. doi: 10.1158/1535-7163.MCT-13-0576. Epub 2014 Apr 16. Mol Cancer Ther. 2014. PMID: 24739393 Free PMC article.

9

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Gopal YN, et al. Among authors: smith pd. Cancer Res. 2014 Dec 1;74(23):7037-47. doi: 10.1158/0008-5472.CAN-14-1392. Epub 2014 Oct 8. Cancer Res. 2014. PMID: 25297634 Free PMC article.

10

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. Bartholomeusz C, et al. Among authors: smith pd. Mol Cancer Ther. 2015 Dec;14(12):2773-81. doi: 10.1158/1535-7163.MCT-15-0243. Epub 2015 Sep 17. Mol Cancer Ther. 2015. PMID: 26384399 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

579 results

Search Page